MPP’s 2026-2030 strategy builds on 15 years of experience to ensure that health innovations reach people in LMICs sooner, more equitably and more sustainably. By combining public health-oriented licensing, technology transfer and strong partnerships, MPP will continue to turn innovation into access, and access into impact.
Our mission is to increase equitable access to innovative medicines and other health technologies through public health-oriented voluntary licensing and technology transfer.
A world in which people in need in low- and middle- income countries (LMICs) have rapid, secure and sustainable access to effective and affordable medical treatments and health technologies.
Recent crises have exposed the fragility of global health systems, while nearly two billion people in low- and middle-income countries (LMICs) still lack access to essential medicines. Funding pressures, health emergencies, rising non-communicable disease (NCD) burdens and concentrated supply chains continue to strain systems and budgets. At the same time, emerging health products and technologies, stronger regional manufacturing efforts and new global frameworks such as the WHO Pandemic Agreement, are creating important opportunities to advance more equitable and secure access to health products in LMICs.
Catalyse affordable access to key quality-assured health products
The Persistent Access Gap
Innovative health products often reach LMICs many years after global launch.
In many cases, high prices limit public procurement and scale-up.
People are left to pay out of pocket or go without treatment.
Why this matters
More effective or better tolerated health products made available within the shortest possible timeframe can contribute to reducing mortality, improving quality of life and enhancing equity. This can also relieve pressure on health systems.
How we work
Identifying priorities together to select the most impactful products
Developing licences and access partnerships
Implementing agreements to deliver on access across regions
Supporting inclusion of access commitments in health R&D
Disseminating strategic information that supports buyers, implementers, manufacturers, innovators and access advocates to make informed decisions
Working in partnership with key market shaping organisations, such as Unitaid
Each licence helps turn innovation into earlier, more affordable access for people in LMICs
Innovative products with strong public health impact, including paediatric and long-acting formulations
Infectious diseases – including treatment and prevention of HIV, TB, viral hepatitis
Non-communicable diseases, including oncology and cardiometabolic diseases
Maternal and child health
Closer integration with national health systems by supporting manufacturing and scale-up of priority health products
6-8
Product licensed
20-25
Access commitments concluded with R&D organisation and funders
Advance diversified and sustainable manufacturing of health products and technologies
Supply insecurity
Recent crises highlighted supply vulnerability when manufacturing capacity is concentrated in a few countries.
02A mix of export controls, supply constraints, price volatility and a focus on more profitable markets, have resulted in widespread supply disruptions in many LMICs with significant consequences for access to vaccines, medicines and diagnostics.
Without diversified and sustainable manufacturing, supply disruption will continue. Supply security enables greater responsiveness to local needs and greater resilience in times of crisis or emergencies contributing to national sovereignty.
MPP catalyses the early availability and affordability of innovative health products in LMICS through its licensing agreements and with its manufacturing partners.
Diversifying licensees across regions
Assessing opportunities suitable for regional production
Matching suppliers with recipients and exploring partnership opportunities
Supporting streamlined technology transfer between sender and receiver
Contributing to sustainable manufacturing ecosystems
Sustainable regional manufacturing strengthens access and supply resilience over time.
Manufacturing of priority health products for LMICS
Regional and local production ecosystems
Focus on building capabilities to manufacture key platform technologies
Sustainability, affordability and quality assurance
10-12
Agreements signed with regional manufacturers
4-6
Partnerships established with governments and regional organisations
Strengthen equitable health emergency preparedness and response
COVID-19 exposed deep inequities in access to vaccines, therapeutics and diagnostics.
Manufacturing capacity for key platform technologies is limited in some regions.
Global systems remain fragmented and reactive, with limited pre-established access pathways.
Licensing and technology transfer contribute to timely and equitable access to pandemic-related health products, so that future health emergencies do not repeat inequities seen during Covid-19.
MPP engages with developers and manufacturers earlier and across regions to enable diversified manufacturing of health products for future health emergencies.
Advocating for geographically diversified manufacturing of pandemic-related products through licensing and technology transfer
Developing a network of pre-assessed geographically diverse manufacturers that can contribute during health emergencies
Engaging early with developers to establish access strategies
Leveraging regional manufacturing projects to support preparedness for future health emergencies
Assembling a pool of technology transfer experts to support the work
Pandemic-prone pathogens, including influenza and other emerging threats
Health products and technologies relevant to emergency response
Technology platforms, including mRNA, that support rapid adaptation and scale-up
Collaboration with regional and global partners to maintain readiness and coordination
25-30
developers and manufacturers collaborating on access to pandemic-related technologies
8-12
mRNA product development initiatives and agreements facilitated
Between 2010-2030,
will have been supplied in LMICs thanks to MPP’s public health oriented voluntary licensing and technology transfer
MPP’s 2026-2030 strategy builds on 15 years of experience to ensure that health innovations reach people in LMICs sooner, more equitably and more sustainably.
Operational Efficiency Directing resources where impact is greatest.
Ensuring digital upgrades reduce bureaucratic cost and burden on staff.
Effective Partnerships Collective action across the access ecosystem.
Working with governments, industry, civil society and global partners to achieve shared goals.
Skilled Human Resources Expertise that delivers at scale.
A diverse, multidisciplinary team navigating complex environments with commitment, courage, generosity and respect.
Sustainable Finance Stability that enables long-term impact.
Transparent, disciplined management of a five-year funding framework.
Our work is defined not just by what we do, but by the principles that guide how we do it.
Driven by public health needs and outcomes.
Adapting to evolving needs and providing context specific solutions.
Ensuring high standards for all licensed products.
Strengthening other access initiatives to reinforce the global health ecosystem.
Working in partnership to maximise impact.
Operating openly and information available publicly.
Building long-term, effective business cases.
With billions of doses of treatments supplied through access-oriented voluntary licensing since 2010, MPP’s work has had tremendous impact.
patient-years of treatment supplied
additional deaths averted through MPP licensing
additional DALYs averted through MPP licensing
saved from the procurement of more affordable health prodcuts (USD$)
MPP measures the economic and health benefits of its work for people in LMICS using a rigorous peer-reviewed impact assessment methodology. Central to the methodology is the comparison of what has happened as a result of MPP’s intervention and what would have happened without that intervention. This enables MPP to quantify how many additional health products have been supplied thanks to MPP’s licences, including through the work of its multiple partners. In turn, MPP’s impact models show the number of people that have benefitted directly from its work – living healthier, longer lives, as well as the savings that have been generated for the global health community through the procurement of more affordable health products.
Over the 2026-2030 strategy period, MPP will continue to collect data on its impact on an annual basis, and publish the results on its website. In particular, MPP will track the following indicators: DALYS averted, deaths averted, infections averted and economic savings. In addition, in relation to strategic goals 2 and 3 in particular, MPP will also start to track and report on the production capacity enhanced and created in LMICS through its technology transfer activities.
Founder & Funder since 2010